Nebulized colistin sulfate plus intravenous antibiotics in mechanically ventilated gram-negative pneumonia

Phase 4, randomised, double-blind trial in pneumonia and ventilator-associated pneumonia (VAP) comparing Nebulized colistin sulfate plus intravenous antibiotics with Nebulized saline placebo plus intravenous antibiotics (2 arms). Primary endpoint: Change in infection biomarkers, etiology and organ function from baseline to days 3, 5, 10 and status at day 28. Planned start Oct 2020; status: not yet recruiting.